Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables (2016 - 2025)

Historic Receivables for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $676000.0.

  • Lineage Cell Therapeutics' Receivables rose 6691.36% to $676000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $676000.0, marking a year-over-year increase of 6691.36%. This contributed to the annual value of $638000.0 for FY2024, which is 1436.24% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Receivables stood at $676000.0 for Q3 2025, which was up 6691.36% from $256000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Receivables registered a high of $51.4 million during Q4 2021, and its lowest value of $77000.0 during Q1 2024.
  • In the last 5 years, Lineage Cell Therapeutics' Receivables had a median value of $406000.0 in 2023 and averaged $3.1 million.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Receivables was 128427500.0% (2021), while the steepest drop was 9954.66% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables (Quarter) stood at $51.4 million in 2021, then plummeted by 98.29% to $881000.0 in 2022, then fell by 15.44% to $745000.0 in 2023, then fell by 14.36% to $638000.0 in 2024, then increased by 5.96% to $676000.0 in 2025.
  • Its Receivables stands at $676000.0 for Q3 2025, versus $256000.0 for Q2 2025 and $213000.0 for Q1 2025.